Announced
Completed
Synopsis
Two venture capital firms Foresite Capital and F-Prime Capital completed a $30m funding round in Genomics, a biotech company. Additional investors include Oxford Sciences Innovation and Lansdowne Partners. “We are delighted to be supported by leading life sciences investors who share our vision. We have known for over 50 years that genetics plays a key role in risk for all the common chronic diseases and cancers, and now we have a robust way to calculate that risk,” Sir Peter Donnelly, Genomics Co-Founder and CEO.
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
By continuing, you agree to our Terms & Conditions and our Data Privacy Policy
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.